Chemomab Therapeutics to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide a Business Update
Chemomab Therapeutics (Nasdaq: CMMB) will present its Q4 and full-year 2022 financial results on March 31, 2023, at 8:00 am Eastern Time. The management team will review the company’s performance and discuss future developments during the call, which includes a live question-and-answer session. Notably, the company focuses on developing therapeutics to address fibro-inflammatory diseases. Their key product, CM-101, aims to treat severe diseases related to fibrosis and inflammation, with recent positive results from clinical studies. A replay of the event will be available for 90 days on their website.
- Upcoming discussion of Q4 and full-year 2022 results may boost investor confidence.
- Encouraging Phase 2 trial results for CM-101 may indicate strong potential for future revenue.
- None.
During the event, Chemomab's management team will review fourth quarter and full-year 2022 performance, discuss recent and upcoming developments and conduct a live question-and-answer session.
A replay of the call will be available on Chemomab's website for 90 days at www.chemomab.com.
Live Webcast and Conference Call at
Click this Webcast link to access the live webcast or replay.
The live webcast and replay can also be accessed at the News & Events section of the Investors page on the Chemomab website at investors.chemomab.com/events.
Conference Call Access via Telephone
US Investors: | +1 (877) 407-9208 |
+1 (201) 493-6784 | |
Conference Passcode: | #13735392 |
Or click on Call me™ for instant telephone access to the event
Please call 5-10 minutes before the scheduled start time, enter the conference passcode and ask the operator for the Chemomab conference call.
About
Chemomab is a clinical stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated good tolerability along with the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. Encouraging results from a Phase 2 liver fibrosis biomarker study in NASH patients and an investigator study of CM-101 in COVID-19 patients with severe lung injury were recently reported, and a Phase 2 trial in primary sclerosing cholangitis patients is ongoing. Chemomab expects to open a Phase 2 systemic sclerosis trial for patient enrollment around midyear of 2023. For more information on Chemomab, visit chemomab.com.
Contacts:
Investor Relations: | Investors & Media: |
Phone: +1 (917) 734-7387 | Consulting Vice President |
Investor & Public Relations, |
View original content to download multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-discuss-fourth-quarter-and-full-year-2022-financial-results-and-provide-a-business-update-301774727.html
SOURCE
FAQ
When will Chemomab discuss its financial results?
What is the focus of Chemomab Therapeutics?
What has been reported about CM-101?
